P273 THE PATHOLOGICAL PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE CORRELATES WITH GUT MICROBIOTA COMPOSITION IN MICE: FROM NON-ALCOHOLIC FATTY LIVER TO NON-ALCOHOLIC STEATOHEPATITIS

2014 ◽  
Vol 60 (1) ◽  
pp. S155-S157
Author(s):  
J. Peng ◽  
F. Huang ◽  
X. Li ◽  
L. Chen ◽  
Q. Feng ◽  
...  
Keyword(s):  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Microbiota Composition ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Steatohepatitis ◽  
Alcoholic Fatty Liver Disease ◽  
Gut Microbiota Composition

Pure total flavonoids from citrus attenuate non-alcoholic fatty liver disease in mice via the gut microbiota

2020 ◽  
Author(s):  
Beihui He ◽  
Jianping Jiang ◽  
Zheng Shi ◽  
Dawei Cui ◽  
Sumei Xu ◽  
...  
Keyword(s):  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Total Flavonoids ◽  
Alcoholic Fatty Liver ◽  
Composition And Structure ◽  
Rdna Sequencing ◽  
Alcoholic Fatty Liver Disease ◽  
Gut Microbiota Composition

Abstract Background An increasing number of studies suggest that gut microbiota composition and structure contribute to the pathophysiology of non-alcoholic fatty liver disease(NAFLD),and the gut microbiota has been proposed as a new target in the treatment of diet-induced NAFLD. In this study, we aimed to investigate the effects of pure total flavonoids from citrus (PTFC) on NAFLD and gut microbiota dysbiosis in high-fat diet (HFD)-fed mice and to further investigate whether the attenuation of NAFLD is related to the modulation of the gut microbiota. Results PTFC intervention could significantly attenuate symptoms in mice with HFD-induced NAFLD.Based on the results of 16S rDNA sequencing, PTFC treatment could increase the phylogenetic diversity of the HFD-induced microbiota. PTFC intervention could significantly restore the HFD-induced increases in the relative abundances of Bacteroidaceae and Christensenellaceae. Conclusion Our results suggested that PTFC could serve as a novel candidate for the prevention of NAFLD by modulating the gut microbiota.

scholarly journals Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review

2020 ◽  
Vol 21 (17) ◽  
pp. 5999
Author(s):  
Yi-Hsun Chen ◽  
Wei-Kai Wu ◽  
Ming-Shiang Wu
Keyword(s):  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Therapeutic Strategies ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Steatohepatitis ◽  
Gut Barrier Function ◽  
And Function ◽  
Alcoholic Fatty Liver Disease ◽  
Gut Microbiota Composition

Even though advancement in medicine has contributed to the control of many diseases to date, cancer therapy continues to pose several challenges. Hepatocellular carcinoma (HCC) etiology is multifactorial. Recently, non-alcoholic fatty liver disease (NAFLD) has been considered as an important risk factor of HCC. NAFLD can be divided into non-alcoholic simple fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) based on histopathological features. Recently, studies have indicated that the gut microbiota is associated with NAFLD and HCC. Therefore, in this review, we have discussed the effects of gut microbiota-related mechanisms, including dysbiosis and gut barrier function, and gut microbiota-derived metabolites on NAFLD and HCC pathogenesis and the potential therapeutic strategies for NAFLD and HCC. With a better understanding of the gut microbiota composition and function, new and improved diagnostic, prognostic, and therapeutic strategies for common liver diseases can be developed.

scholarly journals Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis

Cells ◽  
2020 ◽  
Vol 9 (1) ◽  
pp. 176 ◽  
Author(s):  
Sergio Quesada-Vázquez ◽  
Gerard Aragonès ◽  
Josep M Del Bas ◽  
Xavier Escoté
Keyword(s):  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Close Relation ◽  
Alcoholic Fatty Liver ◽  
Liver Functions ◽  
Specific Species ◽  
Alcoholic Fatty Liver Disease ◽  
Gut Microbiota Composition

Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common liver disease in the world. NAFLD is principally characterized by an excessive fat accumulation in the hepatocytes. Diet is considered as one of the main drivers to modulate the composition of gut microbiota, which participate in different processes, affecting human metabolism. A disruption in the homeostasis of gut microbiota may lead to dysbiosis, which is commonly reflected by a reduction of the beneficial species and an increment in pathogenic microbiota. Gut and liver are in close relation due to the anatomical and functional interactions led by the portal vein, thus altered intestinal microbiota might affect liver functions, promoting inflammation, insulin resistance and steatosis, which is translated into NAFLD. This review will highlight the association between diet, gut microbiota and liver, and how this axis may promote the development of NAFLD progression, discussing potential mechanisms and alterations due to the dysbiosis of gut microbiota. Finally, it will revise the variations in gut microbiota composition in NAFLD, and it will focus in specific species, which directly affect NAFLD progression.

Prevalence, diagnosis and treatment with 3 different statins of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in military personnel. Do genetics play a role?

2020 ◽  
Vol 18 ◽  
Author(s):  
Georgios Sfikas ◽  
Michael Psallas ◽  
Charalambos Koumaras ◽  
Konstantinos Imprialos ◽  
Evangelos Perdikakis ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Military Personnel ◽  
Fatty Liver Disease ◽  
Exercise Group ◽  
Severe Form ◽  
Laboratory Evaluation ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Steatohepatitis ◽  
Alcoholic Fatty Liver Disease

Background: Non-alcoholic fatty liver disease (NAFLD) and its severe form, non-alcoholic steatohepatitis (NASH), are major health problems worldwide. Genetics may play a role in the pathogenesis of NAFLD/NASH. Aim: To investigate the prevalence of NAFLD/NASH in 5,400 military personnel and evaluate the effect of treatment with 3 statins on NAFLD/NASH using 2 non-invasive scores [NAFLD Activity Score (NAS); Fibrosis-4 score (FIB-4)]. Methods: During the mandatory annual medical check-up, military personnel underwent a clinical and laboratory evaluation. Participants with NAFLD/NASH were randomised to 4 groups (n=151 each): dietexercise, atorvastatin, rosuvastatin or pitavastatin for 1 year (i.e. until the next routine evaluation). Results: From all the participants, 613 had NAFLD/NASH (prevalence 11.3 vs 39.8% in the general population, p<0.001); 604 consented to participate in the study. After a year of treatment, the diet-exercise group showed no significant changes in both scores (NAS 4.98 baseline vs 5.62, p=0.07; FIB-4 3.42 vs 3.52, p=0.7). For the atorvastatin group, both scores were reduced (NAS 4.97 vs 1.95, p<0.001, FIB-4 3.56 vs 0.83, p<0.001), for rosuvastatin (NAS 5.55 vs 1.81, p<0.001, FIB-4 3.61 vs 0.79, p<0.001), and for pitavastatin (NAS 4.89 vs 1.99, p<0.001, FIB-4 3.78 vs 0.87, p<0.001). Conclusions : Atorvastatin, rosuvastatin and pitavastatin have a beneficial and safe effect in NAFLD/NASH patients as recorded by the improvement in the NAS (representing NAFLD activity) and FIB-4 (representing liver fibrosis) scores. Since both those with and without NAFLD/NASH shared several baseline characteristics, genetics may play a role in the pathogenesis of NAFLD/NASH and its treatment with statins.

scholarly journals Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review

Foods ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 1719
Author(s):  
Valentina Castillo ◽  
Fernanda Figueroa ◽  
Karoll González-Pizarro ◽  
Paz Jopia ◽  
Claudia Ibacache-Quiroga
Keyword(s):  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Communicable Disease ◽  
Anthropometric Parameters ◽  
Alcoholic Fatty Liver ◽  
Risks Factors ◽  
Alcoholic Fatty Liver Disease ◽  
Non Communicable Disease

Non-alcoholic fatty liver disease (NAFLD) is a chronic non-communicable disease, with a prevalence of 25% worldwide. This pathology is a multifactorial illness, and is associated with different risks factors, including hypertension, hyperglycemia, dyslipidemia, and obesity. Beside these predisposing features, NAFLD has been related to changes in the microbiota, which favor the disease progression. In this context, the modulation of the gut microbiota has emerged as a new therapeutic target for the prophylaxis and treatment of NAFLD. This review describes the changes in the gut microbiota associated with NAFLD and the effect of probiotics, prebiotics, and synbiotics on the gut microbiota, liver damage, anthropometric parameters, blood lipids, inflammation markers and insulin resistance in these patients.

Sign in / Sign up

Export Citation Format

Share Document